logo-loader
viewCellmid Limited

Cellmid Ltd secures funds to launch hair loss product in U.S.

Cellmid Ltd has received commitments to raise $3 million.

cellmid_evolis-vivid_hair-products-757.jpg
Funds will be used to launch the evolis® in the U.S.

Cellmid Ltd (ASX:CDY) has received commitments to raise $3 million through the placement of shares to sophisticated and institutional investors priced at $0.03.

Funds raised will be used to launch the evolis® FGF5 inhibitor hair loss products in the U.S. market.

Together with the recent $1.2 million raised through the exercise of options, funds will allow Cellmid to invest into the launch through product manufacture, digital and social media, salons and high end retail distribution.

Cellmid recently recorded over $1 million in sales for its hair loss products during the September quarter for the first time ever.

The company’s consumer health business currently sells its hair loss products in Australia and Japan.


Background

Cellmid has two business segments, consumer health and its midkine (MK) portfolio.

The company holds the largest and most comprehensive portfolio of intellectual property relating to the MK and FGF5 globally, and its consumer health division currently sells hair growth products in Japan and Australia, which were developed using FGF5 related intellectual property.

Cellmid aims to follow in the footsteps of FGF5 by commercialising its MK portfolio, and it has set up dedicated subsidiaries, Lyramid Limited and Kinera Limited as part of its clinical development plan to commercialise its MK antibody assets.


September quarter sales

The consumer health business sells hair loss products in Australia and Japan and September quarter Australian sales grew by 115%, with the new national advertising program showing strong results.

Overall sales for the quarter were up by 30% compared with the same period last year.

The consumer health business operates at over 70% gross margin providing very strong profitability potential as the business scales up through sales growth and new market entry.

Sales from the U.S. are expected to commence in the current December quarter.


Analysis

Securing funding to support the U.S. market entry is significant as it is the biggest single market for hair loss treatments with combined sales of circa US$3.5 billion annually.

The U.S. market is comprised 57.7% of minoxidil based products, which cater mostly for men.

Cellmid’s evolis® range is formulated for both men and women.

This is particularly important as almost half of those suffering from hair loss are women without a safe and effective treatment alternative.

Colour Collective, Cellmid’s U.S. distribution partner, sees evolis® as a US$100 million plus brand in the U.S.

Shares in Cellmid have been trending positively with the placement price of $0.03 representing a 25% share price increase year to date.

Quick facts: Cellmid Limited

Price: 0.23 AUD

ASX:CDY
Market: ASX
Market Cap: $21.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid Limited outlines key components for FY2020 growth strategy

Cellmid Limited (ASX:CDY) chief executive officer and managing director Maria Halasz updates Proactive Investors on the company’s key components for its FY2020 growth strategy, which includes an exciting new global product to assist ageing hair.  Cellmid is a listed company with health...

on 14/8/19

2 min read